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I.  General Information 
 
The following reagents were purchased and used as received: 9-BBN dimer (Aldrich), NiBr2• 
diglyme (Aldrich; note: hygroscopic), ligands (R,R)-1 and (S,S)-1 (Acros, Aldrich), KOt-Bu 
(Aldrich), n-hexanol (anhydrous; Aldrich), Et2O (anhydrous; Aldrich), and hexanes (anhydrous; 
Aldrich).  The 1-alkenes (precursors to the nucleophiles) were purchased (Aldrich or Alfa Aesar) 
and purified by flash chromatography prior to use, or they were prepared according to 
literature procedures. 
All reactions were carried out in oven-dried glassware under an atmosphere of nitrogen. 
1H NMR and 13C NMR data were collected on a Bruker Avance 400 spectrometer at ambient 
temperature.  HPLC analyses were carried out on an Agilent 1100 series system with Daicel 
CHIRALCEL® columns (internal diameter 4.6 mm, column length 250 mm, particle size 5 µ).  
SFC analyses were carried out on an SFC ProNTo system with Daicel CHIRALCEL® columns 
(internal diameter 4.6 mm, column length 250 mm, particle size 5 µ). 
 
 
II.  Preparation of Electrophiles 
 
The procedures and yields have not been optimized. 
 
  S–2 
O
O
R
MeO
O
O
H
RMgCl
 
General Procedure A: Preparation of lactones.  Anhydrous THF (170 mL) and then methyl 
4-oxobutanoate (3.0 g, 24 mmol; Aldrich) were added to an oven-dried round-bottom flask.  The 
reaction mixture was cooled to –78 °C, and the alkyl Grignard reagent (1.0 equiv) was added 
dropwise to the stirred solution.  The reaction mixture was allowed to warm to room 
temperature and then stirred for 1 hour.  Next, the reaction was quenched by the addition of 
water (5 mL).  A saturated aqueous solution of NH4Cl (60 mL) was then added to the reaction 
mixture, which was stirred until it was homogeneous.  The mixture was transferred to a 
separatory funnel, and the product was extracted with Et2O (100 mL x2) and CH2Cl2 (100 mL).  
The combined organic extracts were washed with brine (100 mL x2), dried over magnesium 
sulfate, filtered, and concentrated to yield the γ-lactone, which was purified by flash 
chromatography with 10→60% Et2O/hexanes. 
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5-Phenethyldihydrofuran-2(3H)-one.  General Procedure A was followed using 
phenylethylmagnesium chloride (24 mL; 1.0 M in THF; Aldrich), which furnished the lactone as 
a colorless oil (3.76 g, 83%).  The spectral data match those described in the literature.1 
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5-Isobutyldihydrofuran-2(3H)-one.  General Procedure A was followed using 
isobutylmagnesium chloride (12 mL; 2.0 M in THF; Aldrich), which furnished the lactone as a 
colorless oil (2.15 g, 66%).  The spectral data match those described in the literature.2 
 
 
                                                
(1) Cossy, J.; Bargiggia, F.; Bouzbouz, S. Org. Lett. 2003, 5, 459–462. 
(2) Pollack, J. A.; Clark, K. M.; Martynowicz, B. J.; Pridgeon, M. G.; Rycenga, M. J.; Stolle, K. E.; 
Taylor, S. K. Tetrahedron: Asymmetry 2007, 18, 1888–1892. 
  S–3 
O( )n
O
R
SOCl2, ZnCl2
Cl ( )n
R
O
Cl
N ( )n
R
O
ClPh
Ph
Ph2NH
n = 0,1  
General Procedure B: Preparation of 3- and 4-chloro-N,N-diphenylamides.3,4  Anhydrous 
ZnCl2 (180 mg, 1.3 mmol note: hygroscopic) was added to an oven-dried two-neck round-
bottom flask, which was then capped with a septum and purged with nitrogen.  Thionyl 
chloride (2.4 mL, 33 mmol) was added to the flask, followed by the lactone (30 mmol).  The 
reaction mixture was stirred at 55 °C for 24 h, during which time it turned dark-brown and 
became viscous.  The excess thionyl chloride was removed under reduced pressure, and the 
acid chloride was used in the next step without further purification. 
The two-neck flask containing the acid chloride was equipped with a reflux condenser and 
purged with nitrogen.  Next, anhydrous benzene (100 mL) and then the diarylamine (33 mmol) 
were added.  The reaction mixture was refluxed for 6 h, and then it was allowed to cool to room 
temperature.  Brine (100 mL) was added, and the mixture was transferred to a separatory 
funnel.  The layers were separated, and the aqueous layer was extracted with Et2O (100 mL).  
The combined organic layers were washed with brine (100 mL), dried over magnesium sulfate, 
filtered, and concentrated to yield the γ- or δ-chloro-N,N-diarylamide.  The product was 
purified by reverse-phase flash chromatography on C-18 silica gel with 10→100% 
acetonitrile/water, followed by normal-phase flash chromatography on silica gel with 10→70% 
Et2O/hexanes, which furnished pure γ- or δ-chloro-N,N-diarylamide (alternatively, if the acid 
chloride is distilled prior to its use in the second step, purification by reverse-phase column 
chromatography is unnecessary).  The products are stable for at least 6 months when stored 
under an inert atmosphere at 0 °C. 
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4-Chloro-N,N-diphenylpentanamide.  The amide was prepared according to General 
Procedure B, using γ-valerolactone and diphenylamine.  White solid (5.14 g, 60%). 
1H NMR (CDCl3) δ 7.33–7.22 (m, 10H), 4.13–4.05 (m, 1H), 2.45–2.42 (m, 2H), 2.22–2.14 (m, 
1H), 1.93–1.83 (m, 1H), 1.47 (d, 3H, J = 6.4 Hz). 
13C NMR (CDCl3) δ 172.1, 142.7, 130.0–125.0 (broad), 58.3, 35.7, 32.4, 25.6. 
FT-IR (film) 3062, 2973, 2926, 1672, 1593, 1492, 1380, 1351, 1291, 756, 702 cm–1. 
MS (EI) m/z (M+H+) calcd for C17H19ClNO: 288, found: 288. 
 
 
                                                
(3) Reppe, W. et al. Annalen der Chemie, Justus Liebigs 1955, 596, 158–224. 
(4) Wise, L. D.; Pattison, I. C.; Butler, D. E.; DeWald, H. A.; Lewis, E. P.; Lobbestael, S. J.; 
Nordin, I. C.; Poschel, B. P. H.; Coughenour, L. L. J. Med. Chem. 1985, 28, 606–612. 
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4-Chloro-N,N-diphenylhexanamide.  The amide was prepared according to General 
Procedure B, using γ-caprolactone and diphenylamine.  White solid (6.02 g, 67%). 
 1H NMR (CDCl3) δ 7.33–7.23 (m, 10H), 3.91–3.88 (m, 1H), 2.46–2.43 (m, 2H), 2.30–2.23 (m, 
1H), 2.01–1.94 (m, 1H), 1.87–1.76 (m, 2H), 0.98 (t, 3H, J = 7.2 Hz). 
13C NMR (CDCl3) δ 172.2, 142.7, 129.7–126.4 (broad), 65.2, 33.6, 32.4, 31.9, 11.0. 
FT-IR (film) 3063, 2969, 2936, 2878, 1673, 1594, 1492, 1452, 1381, 1272, 1162 cm–1. 
MS (EI) m/z (M+H+) calcd for C18H21ClNO: 302, found: 302. 
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4-Chloro-N,N-diphenyloctanamide.  The amide was prepared according to General 
Procedure B, using γ-octanoic lactone and diphenylamine.  White solid (5.50 g, 56%). 
1H NMR (CDCl3) δ 7.33–7.23 (m, 10H), 3.95–3.93 (m, 1H), 2.46–2.43 (m, 2H), 2.23–2.18 (m, 
1H), 1.86–1.82 (m, 1H), 1.69–1.64 (m, 2H), 1.46–1.44 (m, 1H), 1.36–1.24 (m, 3H), 0.86 (t, 3H, J = 7.2 
Hz). 
13C NMR (CDCl3) δ 172.2, 142.7, 128.7–126.4 (broad), 63.7, 38.5, 33.9, 32.3, 28.6, 22.3, 14.0. 
FT-IR (film) 2957, 2871, 2360, 1674, 1594, 1492, 1379, 1280, 756, 701 cm–1. 
MS (EI) m/z (M+H+) calcd for C20H25ClNO: 330, found: 330. 
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4-Chloro-N,N-6-triphenylhexanamide.  The amide was prepared according to General 
Procedure B, using 5-phenethyldihydrofuran-2(3H)-one and diphenylamine.  White solid (3.89 
g, 52%). 
 1H NMR (CDCl3) δ 7.34–7.14 (m, 15H), 3.94–3.90 (m, 1H), 2.84–2.80 (m, 1H), 2.72–2.69 (m, 
1H), 2.46–2.43 (m, 2H), 2.22–2.20 (m, 1H), 2.02–1.92 (m, 3H). 
13C NMR (CDCl3) δ 172.1, 142.7, 141.1, 130.0–125.0 (broad), 128.53, 128.50, 126.1, 62.7, 40.5, 
34.0, 32.7, 32.2. 
FT-IR (film) 3027, 2921, 2360, 2340, 1670, 1593, 1492, 1381, 1293, 1158, 700 cm–1. 
MS (EI) m/z (M+H+) calcd for C24H25ClNO: 378, found: 378. 
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4-Chloro-6-methyl-N,N-diphenylheptanamide.  The amide was prepared according to 
General Procedure B, using 5-isobutyldihydrofuran-2(3H)-one and diphenylamine.  White solid 
(2.40 g, 48%). 
 1H NMR (CDCl3) δ 7.34–7.23 (m, 10H), 4.02–4.00 (m, 1H), 2.48–2.44 (m, 2H), 2.21–2.18 (m, 
1H), 1.88–1.81 (m, 2H), 1.67–1.60 (m, 1H), 1.46–1.41 (m, 1H), 0.88 (d, 3H, J = 6.4 Hz), 0.85 (d, 3H, J 
= 6.4 Hz). 
13C NMR (CDCl3) δ 172.2, 142.7, 130.0–125.0 (broad), 61.8, 47.9, 34.2, 32.3, 25.3, 23.0, 21.4. 
FT-IR (film) 2957, 2360, 1674, 1491, 1381, 1270, 756, 701 cm–1. 
MS (EI) m/z (M+H+) calcd for C20H25ClNO: 330, found: 330. 
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4-Bromo-N,N-diphenylhexanamide.5  In accordance with a literature procedure,6 γ-
caprolactone (8.0 g, 70 mmol) was added to a round-bottom flask that contained HBr in AcOH 
(70 mL; 30% in AcOH).  The flask was equipped with a reflux condenser, and the reaction 
mixture was stirred at room temperature for 2 hours and then at 70 °C for 5 hours.  Next, the 
mixture was allowed to cool to room temperature, and then the AcOH was removed by rotary 
evaporation.  CH2Cl2 (50 mL) and a solution of saturated sodium thiosulfate (50 mL) were then 
added, and the mixture was transferred to a separatory funnel, where the layers were separated.  
The aqueous layer was extracted with CH2Cl2 (50 mL x2), and the combined organic layers were 
washed with brine (50 mL), dried over magnesium sulfate, filtered, and concentrated to furnish 
4-bromohexanoic acid (light-red oil).  The product was used in the following step without 
further purification. 
Anhydrous CH2Cl2 (240 mL) and then oxalyl bromide (20.4 g, 94.5 mmol; Aldrich) were 
added to an oven-dried round-bottom flask under nitrogen.  The solution was cooled to 0 °C, 
and the unpurified 4-bromohexanoic acid (13.7 g, 70.1 mmol) was added.  Next, DMF (1.1 mL, 
14 mmol) was added dropwise, and the reaction was monitored at 0 °C for 2 h, at which time 
gas evolution ended.  The reaction mixture was concentrated to remove the excess oxalyl 
bromide and CH2Cl2, affording 4-bromohexanoyl bromide, which was used without 
purification in the next step. 
The flask was equipped with a reflux condenser and purged with nitrogen.  Anhydrous 
benzene (240 mL) was added, followed by diphenylamine (11.8 g, 69.7 mmol).  The reaction 
mixture was refluxed for 6 h, and then it was allowed to cool to room temperature.  The mixture 
                                                
(5) Wise, L. D.; Pattison, I. C.; Butler, D. E.; DeWald, H. A.; Lewis, E. P.; Lobbestael, S. J.; 
Nordin, I. C.; Poschel, B. P. H.; Coughenour, L. L. J. Med. Chem. 1985, 28, 606–612. 
(6) Sashida, H.; Nakayama, A.; Kaname, M. Synthesis 2008, 3229–3236. 
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was transferred to a separatory funnel, and brine (100 mL) was added.  The layers were 
separated, and the aqueous layer was extracted with Et2O (100 mL).  The combined organic 
layers were washed with brine (50 mL x2), dried over magnesium sulfate, filtered, and 
concentrated.  The product was purified by flash chromatography (10→70% Et2O/hexanes), 
which furnished 4-bromo-N,N-diphenylhexanamide as a white solid (15.0 g, 62% over three 
steps).  This compound is stable for at least 3 months when stored under an inert atmosphere at 
0 °C. 
1H NMR (CDCl3) δ 7.33–7.23 (m, 10H), 4.06–4.02 (m, 1H), 2.48–2.44 (m, 2H), 2.23–2.18 (m, 
1H), 1.88–1.82 (m, 1H), 1.77–1.54 (m, 2H), 0.99 (t, 3H, J = 7.2 Hz). 
13C NMR (CDCl3) δ 172.0, 142.6, 130.6–125.5 (broad), 60.0, 34.2, 34.5, 32.6, 12.1. 
FT-IR (film) 3061, 2969, 1672, 1593, 1492, 1452, 1381, 1271, 756, 702 cm–1. 
MS (EI) m/z (M+H+) calcd for C18H21BrNO: 346, 348, found: 346, 348. 
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5-Chloro-N,N-diphenylhexanamide.  The amide was prepared according to General 
Procedure B, using δ-hexalactone and diphenylamine.  White solid (3.70 g, 41%). 
 1H NMR (CDCl3) δ 7.34–7.23 (m, 10H), 3.91–3.88 (m, 1H), 2.46–2.43 (m, 2H), 2.23–2.18 (m, 
1H), 1.88–1.82 (m, 1H), 1.77–1.54 (m, 2H), 1.00–0.96 (m, 3H). 
13C NMR (CDCl3) δ 172.2, 142.7, 129.3–126.4 (broad), 65.2, 33.6, 32.4, 31.9, 11.0. 
FT-IR (film) 3062, 3038, 2969, 2936, 1673, 1594, 1492, 1452, 1381, 1272, 1162 cm–1. 
MS (EI) m/z (M+H+) calcd for C18H21ClNO: 302, found: 302. 
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4-Chloro-N-methoxy-N-methylhexanamide.  The first step was performed as described in 
General Procedure B. 
Next, N,O-dimethylhydroxylamine hydrochloride (1.9 g, 19 mmol) and Et2O (30 mL) were 
added to a stirred 0 °C solution of potassium carbonate (6.6 g, 48 mmol) in water (30 mL).  Then, 
4-chlorohexanoyl chloride (4.0 g, 24 mmol) was added dropwise over 5 minutes.  The reaction 
mixture was stirred at 0 °C for 30 minutes, and then it was diluted with Et2O (50 mL) and brine 
(50 mL).  The layers were separated, and the aqueous layer was extracted with Et2O (50 mL).  
The combined organic layers were washed with 1N HCl (30 mL), dried over magnesium sulfate, 
filtered, and concentrated.  The product was purified by flash chromatography with 20→90% 
Et2O/hexanes, which furnished the amide as a yellow oil (2.9 g, 79% yield for step 2).  This 
compound is stable for at least 6 months when stored under an inert atmosphere at 0 °C. 
1H NMR (CDCl3) δ 3.91–3.88 (m, 1H), 3.67 (s, 3H), 3.15 (s, 3H), 2.63 (t, 2H, J = 6.8 Hz), 2.16–
2.12 (m, 1H), 1.90–1.70 (m, 3H), 1.01 (t, 3H, J = 7.2 Hz). 
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13C NMR (CDCl3) δ 173.3, 65.0, 61.0, 32.5, 31.9, 31.6, 28.6, 10.7. 
FT-IR (film) 2969, 1775, 1666, 1417, 1386, 1178, 1120, 994, 848, 815 cm–1. 
MS (ESI/APCI) m/z (M+H+) calcd for C8H17ClNO2: 194, found: 194. 
 
 
III.  Preparation of Nucleophiles 
 
General procedure for the preparation of B-alkyl-(9-BBN) reagents.  In a nitrogen-filled 
glovebox, the olefin (6.0 mmol; purified) was added to 9-BBN dimer (3.0 mmol) in a 20-mL vial 
equipped with a stir bar.  Et2O was then added to provide a concentration of 1.5 M of the 
organoborane, and the vial was sealed with a teflon-lined septum cap.  The mixture was heated 
at 40 °C for 1.5 hours (outside of the glovebox), during which time it became homogenous.  The 
solution was allowed to cool to room temperature.  This solution could be stored in a glovebox 
at ambient temperature for 3 months without noticeable degradation. 
Procedure for the preparation of B-phenyl- and B-cyclopropyl-(9-BBN) reagents.  These 
reagents were prepared according to a literature procedure7 by reacting phenylmagnesium 
bromide (3.0 M in Et2O; Aldrich) or cyclopropylmagnesium bromide (0.5 M in Et2O; Aldrich) 
with B-MeO-(9-BBN).  The resulting products were purified by distillation. 
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(Hept-6-en-1-yl)-1H-indole.  The title compound was synthesized via a modification of a 
literature method.8  Anhydrous DMF (7 mL) and indole (1.1 g, 9.4 mmol) were added to an 
oven-dried two-neck round-bottom flask under nitrogen.  The reaction mixture was cooled to 0 
°C, and then NaH (0.21 g, 8.7 mmol) was added, followed by the dropwise addition of 7-bromo-
hept-1-ene (2.0 g, 11.3 mmol).  The reaction was warmed to room temperature and stirred for 5 
hours.  Next, water was added (10 mL), and the mixture was transferred to a separatory funnel.  
Brine (20 mL) was added, and the aqueous layer was extracted with Et2O (50 mL x3).  The 
combined organic layers were dried over magnesium sulfate, filtered, and concentrated.  The 
product was purified by flash chromatography with 5→40% Et2O/hexanes, which furnished the 
1-(hept-6-en-1-yl)-1H-indole as a red oil (1.0 g, 54%). 
1H NMR (CDCl3) δ 8.05–8.04 (m, 1H), 7.67–7.65 (m, 1H), 7.59–7.53 (m, 1H), 7.51–7.50 (m, 1H), 
7.34 (d, 1H, J = 2.2 Hz), 6.88–6.83 (m, 1H), 6.12–6.10 (m, 1H), 5.41–5.35 (m, 2H), 4.29 (t, 2H, J = 7.1 
Hz), 2.38–2.36 (m, 2H), 2.11–2.04 (m, 2H), 1.75–1.68 (m, 2H), 1.64–1.53 (m, 2H). 
13C NMR (CDCl3) δ 139.0, 136.4, 129.1, 128.1, 121.7, 121.4, 119.6, 115.0, 109.8, 101.3, 46.6, 34.0, 
30.5, 28.9, 26.8. 
FT-IR (film) 3074, 2930, 2856, 1640, 1612, 1511, 1484, 1353, 1316, 910, 740 cm–1. 
                                                
(7) Fang, G. Y.; Wallner, O. A.; Di Blasio, N.; Ginesta, X.; Harvey, J. N.; Aggarwal, V. K. J. Am. 
Chem. Soc. 2007, 129, 14632–14639. 
(8) Xenon Pharmaceuticals, Inc. Spiro-Oxindole Compounds and Their Uses as Therapeutic 
Agents. WO2006/110917 A2, October 19, 2006; pp 74–75. 
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MS (EI) m/z (M+H+) calcd for C15H20N: 214, found: 214. 
 
 
IV.  Catalytic Asymmetric γ-Alkylation of Carbonyl Compounds 
 
General procedure for catalytic asymmetric γ-alkylations.  In a nitrogen-filled glovebox, a 
solution of the organoboron reagent (670 µL, 1.0 mmol; 1.5 M) was added to a slurry of 
potassium tert-butoxide (78.5 mg, 0.70 mmol) and 1-hexanol (113 µL, 92 mg, 0.90 mmol) in a 4-
mL vial equipped with a stir bar.  The vial was sealed with a teflon-lined septum cap, and the 
mixture was stirred vigorously for 30 minutes and then used in the next step. 
In a glovebox, NiBr2 • diglyme (17.6 mg, 0.050 mmol), (R,R)-1 (14.5 mg, 0.060 mmol), hexanes 
(3.1 mL), and Et2O (1.4 mL) were added in turn to a 20-mL vial equipped with a stir bar.  The 
vial sealed with a teflon-lined septum cap, and the mixture was stirred vigorously for 45 
minutes (a light-blue slurry forms).  The solution of the activated organoboron reagent was then 
added to the slurry, and the vial was sealed with a teflon-lined cap and stirred for 30 minutes 
(the reaction mixture turns brown).  The electrophile (0.50 mmol in 0.5 mL of Et2O; purified) 
was added to the slurry via syringe, and the vial that contained the electrophile was then rinsed 
with additional Et2O (0.5 mL), and this solution was added to the slurry.  The mixture was 
sealed with a teflon-lined cap and stirred vigorously at room temperature for 24 hours (outside 
of the glovebox).  Next, the reaction mixture was passed through a short plug of silica gel, 
eluting with Et2O.   The solution was concentrated to furnish an oil, which was purified by 
reverse-phase flash chromatography on C-18 silica gel with 10→100% acetonitrile/water. 
A second run was conducted with (S,S)-1. 
 
Glovebox-free procedure for catalytic asymmetric γ-alkylation (Table 1, entry 4).  A 25-mL 
two-neck round-bottom flask equipped with a stir bar was capped with a septum and with a 
hose adapter, which was connected to a Schlenk line.  The flask was placed under vacuum and 
flame-dried.  The flask was then filled with nitrogen, and, under a positive pressure of nitrogen, 
9-BBN dimer (732 mg, 3.0 mmol) was added.  The flask was purged with nitrogen for 3 minutes, 
and then 1-allyl-4-methoxybenzene (890 mg, 6.0 mmol) was added via syringe.  Next, 
anhydrous Et2O was added by syringe to bring the concentration to 1.5 M, and the mixture was 
heated at 40 °C for 1.5 hours, during which time it became homogenous.  The solution was 
allowed to cool to room temperature and then used in the next step. 
A 50-mL two-neck round-bottom flask equipped with a stir bar was capped with a septum 
and with a hose adapter, which was connected to a Schlenk line.  The flask was placed under 
vacuum and flame-dried.  The flask was then filled with nitrogen, and, under a positive 
pressure of nitrogen, potassium tert-butoxide (78.5 mg, 0.70 mmol) was added.  The flask was 
purged with nitrogen for 3 minutes, and then anhydrous 1-hexanol (92 mg, 113 µL, 0.90 mmol) 
and a solution of the B-alkyl-(9-BBN) reagent (670 µL, 1.0 mmol; 1.5 M) were added in turn via 
syringe.  The resulting mixture was stirred vigorously for 30 minutes and then used in the next 
step. 
A 50-mL two-neck round-bottom flask equipped with a stir bar was capped with a septum 
and with a hose adapter, which was connected to a Schlenk line.  The flask was placed under 
vacuum and flame-dried.  The flask was then filled with nitrogen, and, under a positive 
pressure of nitrogen, NiBr2 • diglyme (17.6 mg, 0.050 mmol) and (R,R)-1 (14.5 mg, 0.060 mmol) 
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were added.  The flask was purged with nitrogen for 3 minutes, and then anhydrous hexanes 
(3.1 mL) and Et2O (1.4 mL) were added via syringe.  The mixture was stirred vigorously for 45 
minutes (a light-blue slurry forms).  The solution of the activated B-alkyl-(9-BBN) reagent was 
then transferred to the slurry via cannula, and the reaction mixture was stirred for 30 minutes 
(the reaction mixture turns brown).  The electrophile (151 mg, 0.50 mmol in 0.5 mL of Et2O; in a 
flame-dried flask under nitrogen) was added to this reaction mixture via syringe, and the flask 
that contained the electrophile was rinsed (under nitrogen) with an additional 0.5 mL of Et2O, 
which was also added to the slurry via syringe.  The reaction mixture was stirred vigorously 
under nitrogen for 24 hours at room temperature.  Next, the mixture was passed through a 
short plug of silica gel, eluting with Et2O.  The solution was concentrated to furnish an oil, 
which was purified by reverse-phase flash chromatography on C-18 silica gel with 10→100% 
acetonitrile/water.  Colorless oil (147 mg, 71%; 88% ee). 
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4-Methyl-8-(2-methyl-1,3-dioxolan-2-yl)-N,N-diphenyloctanamide (Table 1, Entry 1).  The 
title compound was prepared according to the general procedure, using 4-chloro-N,N-
diphenylpentanamide (144 mg, 0.50 mmol) and a solution of the alkylborane prepared by 
hydroboration of 2-(but-3-en-1-yl)-2-methyl-1,3-dioxolane9 with 9-BBN dimer (1.5 M in Et2O; 
670 µL, 1.0 mmol).  Colorless oil. 
First run: 125 mg (63%, 84% ee).  Second run: 123 mg (62%, 85% ee). 
The ee was determined by HPLC analysis (CHIRALPAK AD-H, 5% i-PrOH in hexanes; 1.0 
mL/min; retention times (when (R,R)-1 is employed): 32.9 min (minor), 37.9 min (major)). 
1H NMR (CDCl3) δ 7.33–7.21 (m, 10H), 3.92–3.87 (m, 4H), 2.25–2.19 (m, 2H), 1.71–1.61 (m, 
1H), 1.58–1.54 (m, 2H), 1.49–1.40 (m, 1H), 1.30–1.15 (m, 9H), 1.08–0.99 (m, 1H), 0.71 (d, 3H, J = 
6.8 Hz). 
13C NMR (CDCl3) δ 173.5, 143.0, 129.2–126.8 (broad), 110.1, 64.6 (2C), 39.2, 36.6, 33.0, 32.6, 
32.3, 27.1, 24.3, 23.8, 19.4. 
FT-IR (film) 3438, 2941, 2870, 1673, 1595, 1492, 1375, 1273, 1051, 757, 701 cm–1. 
MS (EI) m/z (M+H+) calcd for C25H34NO3: 396, found: 396. 
[α]25D = 0.61 (c = 1.06, CHCl3; obtained with (S,S)-1). 
 
 
                                                
(9) Collins, P. W.; Gasiecki, A. F.; Perkins, W. E.; Gullikson, G. W.; Jones, P. H.; Bauer, R. F. J. 
Med. Chem. 1989, 32, 1001–1006. 
  S–10 
N
Me
O
Ph
Ph
 
5-Cyclohexyl-4-methyl-N,N-diphenylpentanamide (Table 1, Entry 2).  The title compound 
was prepared according to the general procedure, except that the catalyst loading was doubled: 
NiBr2 • diglyme (35.2 mg, 0.10 mmol) and 1 (29 mg, 0.12 mmol).  4-Chloro-N,N-
diphenylpentanamide (144 mg, 0.50 mmol) was used, along with a solution of the alkylborane 
prepared by hydroboration of methylenecyclohexane with 9-BBN dimer (1.5 M in Et2O; 670 µL, 
1.0 mmol).  White solid. 
First run: 96 mg (55%, 90% ee).  Second run: 91 mg (52%, 90% ee). 
The ee was determined by HPLC analysis (CHIRALPAK AD-H, 2% i-PrOH in hexanes; 1.0 
mL/min; retention times (when (R,R)-1 is employed): 19.3 min (minor), 25.0 min (major)). 
1H NMR (CDCl3) δ 7.34–7.25 (m, 10H), 2.31–2.17 (m, 2H), 1.65–1.62 (m, 6H), 1.44–1.36 (m, 
2H), 1.20–1.15 (m, 4H), 1.05–0.95 (m, 1H), 0.95–0.88 (m, 1H), 0.88–0.70 (m, 5H). 
13C NMR (CDCl3) δ 173.7, 143.1, 129.2–125.0 (broad), 44.9, 34.8, 34.0, 33.3, 33.0, 32.9, 29.2, 26.7, 
26.4, 26.3, 19.6. 
FT-IR (film) 2921, 2850, 2360, 1675, 1593, 1491, 1449, 1375, 1272, 755, 701 cm–1. 
MS (EI) m/z (M+H+) calcd for C24H32NO: 350, found: 350. 
[α]24D = –1.2 (c = 1.26, CHCl3; obtained with (S,S)-1). 
 
 
N
Et
O
(CH2)5–OTBSPh
Ph
 
9-((tert-Butyldimethylsilyl)oxy)-4-ethyl-N,N-diphenylnonanamide (Table 1, Entry 3; eq 6).  
The title compound was prepared according to the general procedure, using 4-chloro-N,N-
diphenylhexanamide (151 mg, 0.50 mmol) and a solution of the alkylborane prepared by 
hydroboration of tert-butyldimethyl(pent-4-en-1-yloxy)silane10 with 9-BBN dimer (1.5 M in 
Et2O; 670 µL, 1.0 mmol).  Colorless oil. 
First run: 178 mg (76%, 90% ee).  Second run: 168 mg (72%, 92% ee). 
The ee was determined by HPLC analysis (CHIRALPAK AD-H, 1% i-PrOH in hexanes; 1.0 
mL/min; retention times (when (R,R)-1 is employed): 12.6 min (minor), 13.2 min (major)). 
1H NMR (CDCl3) δ 7.33–7.22 (m, 10H), 3.55 (t, 2H, J = 6.8 Hz), 2.22–2.18 (m, 2H), 1.61–1.56 (m, 
2H), 1.45–1.42 (m, 2H), 1.19–1.10 (m, 9H), 0.86 (s, 9H), 1.06 (t, 3H, J = 7.2 Hz), 0.01 (s, 6H). 
13C NMR (CDCl3) δ 173.7, 143.1, 129.3–126.6 (broad), 63.3, 38.5, 32.9, 32.8, 29.0, 26.3, 26.2, 26.0, 
25.6, 18.4, 10.7, –4.9, –5.2. 
FT-IR (film) 2929, 2857, 1676, 1594, 1492, 1462, 1360, 1255, 1098, 835, 775, 755, 701 cm–1. 
MS (EI) m/z (M+H–t-Bu+) calcd for C29H46NO2Si: 468, found: 411. 
[α]24D = –0.84 (c = 1.1, CHCl3; obtained with (S,S)-1). 
                                                
(10) Liang, B.; Negishi, E.-i. Org. Lett. 2008, 10, 193–195. 
  S–11 
When 4-bromo-N,N-diphenylhexanamide (173 mg, 0.50 mmol) was employed as the 
electrophile (eq 6): First run: 164 mg (60%, 86% ee).  Second run: 166 mg (62%, 86% ee). 
 
 
OMe
N
Et
O
Ph
Ph
 
4-Ethyl-7-(4-methoxyphenyl)-N,N-diphenylheptanamide (Table 1, Entry 4).  The title 
compound was prepared according to the general procedure, using 4-chloro-N,N-
diphenylhexanamide (151 mg, 0.50 mmol) and a solution of the alkylborane prepared by 
hydroboration of 1-allyl-4-methoxybenzene with 9-BBN dimer (1.5 M in Et2O; 670 µL, 1.0 
mmol).  Colorless oil. 
First run: 164 mg (79%, 89% ee).  Second run: 166 mg (80%, 88% ee). 
The ee was determined by HPLC analysis (CHIRALPAK AD-H, 10% i-PrOH in hexanes; 1.0 
mL/min; retention times (when (R,R)-1 is employed): 17.2 min (minor), 18.4 min (major)). 
1H NMR (CDCl3) δ 7.33–7.20 (m, 10H), 7.02 (d, 2H, J = 8.4 Hz), 6.78 (d, 2H, J = 4.0 Hz), 3.76 (s, 
3H), 2.43 (t, 2H, J = 6.8 Hz), 2.25–2.16 (m, 2H, J = 8.0 Hz), 1.61–1.54 (m, 2H), 1.49–1.41 (m, 2H), 
1.30–1.18 (m, 5H), 0.77 (t, 3H, J = 7.6 Hz). 
13C NMR (CDCl3) δ 173.7, 157.7, 143.1, 134.8, 129.3, 127.4–125.6 (broad), 113.7, 55.3, 38.4, 35.3, 
32.8, 32.4, 29.0, 28.6, 25.6, 10.7. 
FT-IR (film) 2931, 1674, 1594, 1558, 1540, 1512, 1491, 1456, 1245, 1177, 1035, 756, 702 cm–1. 
MS (EI) m/z (M+H+) calcd for C28H34NO2: 416, found: 416. 
[α]24D = 1.8 (c = 1.26, CHCl3; obtained with (R,R)-1). 
 
 
N
N
Et
O
Ph
Ph
(CH2)7
 
4-Ethyl-11-(1H-indol-1-yl)-N,N-diphenylundecanamide (Table 1, Entry 5).  The title 
compound was prepared according to the general procedure, using 4-chloro-N,N-
diphenylhexanamide (151 mg, 0.50 mmol) and a solution of the alkylborane prepared by 
hydroboration of 1-(hept-6-en-1-yl)-1H-indole with 9-BBN dimer (1.5 M in Et2O; 670 µL, 1.0 
mmol).  Yellow oil. 
First run: 147 mg (61%, 89% ee).  Second run: 154 mg (64%, 90% ee). 
The ee was determined by SFC analysis (CHIRALPAK AD-H, 10% MeOH; 3.0 mL/min; 
retention times (when (R,R)-1 is employed): 43.0 min (major), 47.6 min (minor)). 
1H NMR (CDCl3) δ 7.66 (d, 1H, J = 8.0 Hz), 7.28–7.26 (m, 5H), 7.25–7.21 (m, 7H), 7.14–7.10 (m, 
2H), 6.52–6.51 (m, 1H), 4.12 (t, 2H, J = 6.8 Hz), 2.26 (t, 2H, J = 7.6 Hz), 1.85–1.82 (m, 2H), 1.67–
1.62 (m, 2H), 1.30–1.11 (m, 13H), 0.81 (t, 3H, J = 6.6 Hz). 
  S–12 
13C NMR (CDCl3) δ 173.9, 143.3, 136.2, 129.4–127.2 (broad), 128.8, 128.0, 121.5, 121.2, 119.4, 
109.6, 101.0, 46.6, 38.7, 33.0, 32.9, 30.5, 30.1, 29.5, 29.2, 27.2, 26.6, 25.8, 10.9. 
FT-IR (film) 2927, 2855, 1673, 1592, 1491, 1464, 1315, 740, 702 cm–1. 
MS (EI) m/z (M+H+) calcd for C33H41N2O: 481, found: 481. 
[α]24D =  0.33 (c = 1.82, CHCl3; obtained with (S,S)-1). 
 
 
N
Et
O
(CH2)5–CNPh
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9-Cyano-4-ethyl-N,N-diphenylnonanamide (Table 1, Entry 6).  The title compound was 
prepared according to the general procedure, except that the reaction was heated to 60 °C in i-
Pr2O, using 4-chloro-N,N-diphenylhexanamide (151 mg, 0.50 mmol) and a solution of the 
alkylborane prepared by hydroboration of hex-5-enenitrile with 9-BBN dimer (1.5 M in Et2O; 
670 µL, 1.0 mmol).  Colorless oil. 
First run: 94 mg (52%, 68% ee).  Second run: 91 mg (50%, 70% ee). 
The ee was determined by HPLC analysis (CHIRALPAK AD-H, 5% i-PrOH in hexanes; 1.0 
mL/min; retention times (when (R,R)-1 is employed): 55.8 min (minor), 59.2 min (major)). 
1H NMR (CDCl3) δ 7.28–7.18 (m, 10H), 2.28 (t, 2H, J = 7.2 Hz), 2.24–2.18 (m, 2H), 1.61–1.55 (m, 
5H), 1.40–1.29 (m, 2H), 1.25–1.00 (m, 6H), 0.74 (t, 3H, J = 7.0 Hz). 
13C NMR (CDCl3) δ 173.6, 143.0, 130.2–126.8 (broad), 119.9, 38.4, 32.7, 32.4, 29.0, 28.9, 25.7, 
25.5, 25.3, 17.1, 10.7. 
FT-IR (film) 2931, 2859, 1671, 1595, 1491, 1452, 1357, 1273, 757, 703 cm–1. 
MS (EI) m/z (M+H+) calcd for C24H31N2O: 363, found: 363. 
[α]24D = –1.3 (c = 1.45, CHCl3; obtained with (R,R)-1). 
 
 
F
N
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4-(3-(4-Fluorophenyl)propyl)-N,N-diphenyloctanamide (Table 1, Entry 7).  The title 
compound was prepared according to the general procedure, using 4-chloro-N,N-
diphenyloctanamide (165 mg, 0.50 mmol) and a solution of the alkylborane prepared by 
hydroboration of 1-allyl-4-fluorobenzene with 9-BBN dimer (1.5 M in Et2O; 670 µL, 1.0 mmol).  
Colorless oil. 
First run: 134 mg (62%, 89% ee).  Second run: 140 mg (65%, 90% ee). 
The ee was determined by HPLC analysis (CHIRALPAK AD-H, 3% i-PrOH in hexanes; 1.0 
mL/min; retention times (when (R,R)-1 is employed): 19.2 min (minor), 20.8 min (major)). 
1H NMR (CDCl3) δ 7.32–7.20 (m, 10H), 7.07–7.03 (m, 2H), 6.93–6.89 (m, 2H), 2.46 (t, 2H, J = 7.6 
Hz), 2.20–2.16 (m, 2H), 1.61–1.56 (m, 2H), 1.48–1.44 (m, 2H), 1.24–1.07 (m, 9H), 0.80 (t, 3H, J = 7.2 
Hz). 
  S–13 
13C NMR (CDCl3) δ 173.6, 161.2 (d, J = 964 Hz), 143.0, 138.2, 129.7, 129.6–126.6 (broad), 115.0, 
114.8, 36.9, 35.5, 35.4, 33.1, 32.9, 29.4, 28.7, 28.4, 23.0, 14.1. 
FT-IR (film) 2928, 2858, 2361, 2340, 1675, 1598, 1509, 1491, 1362, 1273, 1220, 1157, 832, 756, 
702, 668 cm–1. 
MS (EI) m/z (M+H+) calcd for C29H35FNO: 432, found: 432. 
[α]24D = 1.9 (c = 1.21, CHCl3; obtained with (S,S)-1). 
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7-(4-Methoxyphenyl)-4-phenethyl-N,N-diphenylheptanamide (Table 1, Entry 8).  The title 
compound was prepared according to the general procedure, using 4-chloro-N,N-6-
triphenylhexanamide (189 mg, 0.50 mmol) and a solution of the alkylborane prepared by 
hydroboration of 1-allyl-4-methoxybenzene with 9-BBN dimer (1.5 M in Et2O; 670 µL, 1.0 
mmol).  Colorless oil. 
First run: 202 mg (82%, 88% ee).  Second run: 206 mg (84%, 88% ee). 
The ee was determined by HPLC analysis (CHIRALPAK AD-H, 3% i-PrOH in hexanes; 1.0 
mL/min; retention times (when (R,R)-1 is employed): 56.7 min (minor), 65.3 min (major)). 
1H NMR (CDCl3) δ 7.33–7.14 (m, 13H), 7.07–7.02 (m, 4H), 6.81–6.79 (m, 2H), 3.77 (s, 3H), 2.48–
2.43 (m, 4H), 2.25–2.20 (m, 2H), 1.70–1.68 (m, 2H), 1.54–1.35 (m, 5H), 1.22–1.19 (m, 2H). 
13C NMR (CDCl3) δ 173.5, 157.7, 143.0, 142.9, 134.7, 130.0–125.0 (broad), 129.3, 128.4, 128.3, 
125.7, 113.7, 55.3, 53.5, 36.6, 35.3, 32.9, 32.71, 32.66, 29.3, 28.5. 
FT-IR (film) 2930, 2857, 1672, 1594, 1511, 1491, 1452, 1245, 1177, 1033, 756, 701 cm–1. 
MS (EI) m/z (M+H+) calcd for C34H38NO2: 492, found: 492. 
[α]24D = 0.84 (c = 1.12, CHCl3; obtained with (S,S)-1). 
 
 
N
i-Bu
O
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4-Isobutyl-N,N,7-triphenylheptanamide (Table 1, Entry 9).  The title compound was 
prepared according to the general procedure, using 4-chloro-6-methyl-N,N-
diphenylheptanamide (165 mg, 0.50 mmol) and a solution of the alkylborane prepared by 
hydroboration of allylbenzene with 9-BBN dimer (1.5 M in Et2O; 670 µL, 1.0 mmol).  Colorless 
oil. 
First run: 124 mg (60%, 82% ee).  Second run: 128 mg (62%, 82% ee). 
The ee was determined by HPLC analysis (CHIRALPAK AD-H, 3% i-PrOH in hexanes; 1.0 
mL/min; retention times (when (R,R)-1 is employed): 15.8 min (minor), 17.9 min (major)). 
  S–14 
1H NMR (CDCl3) δ 7.32–7.10 (m, 15H), 2.48 (t, 2H, J = 7.6 Hz), 2.21–2.16 (m, 2H), 1.60–1.56 (m, 
2H), 1.53–1.40 (m, 3H), 1.39–1.30 (m, 1H), 1.14–1.10 (m, 2H), 0.96–0.95 (m, 1H), 0.88–0.86 (m, 1H), 
0.77–0.74 (m, 6H). 
13C NMR (CDCl3) δ 173.7, 143.1, 142.7, 129.2–125.0 (broad), 128.5, 128.3, 125.7, 43.4, 36.4, 34.6, 
33.3, 32.6, 29.6, 28.2, 25.2, 23.1, 22.9. 
FT-IR (film) 2952, 2929, 1675, 1594, 1492, 1453, 1364, 1271, 755, 700 cm–1. 
MS (EI) m/z (M+H+) calcd for C29H36NO: 414, found: 414. 
[α]24D = 0.79 (c = 1.07, CHCl3; obtained with (R,R)-1). 
 
 
N
O
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Ph
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(CH2)3(p-anisyl)
 
8-(4-Methoxyphenyl)-5-methyl-N,N-diphenyloctanamide (eq 7).  The title compound was 
prepared according to the general procedure, using 5-chloro-N,N-diphenylhexanamide (144 mg, 
0.50 mmol) and a solution of the alkylborane prepared by hydroboration of 1-allyl-4-
methoxybenzene with 9-BBN dimer (1.5 M in Et2O; 670 µL, 1.0 mmol).  Colorless oil. 
First run: 131 mg (63%, 83% ee).  Second run: 135 mg (65%, 84% ee). 
The ee was determined by HPLC analysis (CHIRALPAK AD-H, 10% i-PrOH in hexanes; 1.0 
mL/min; retention times (when (R,R)-1 is employed): 18.3 min (minor), 19.8 min (major)). 
1H NMR (CDCl3) δ 7.33–7.21 (m, 10H), 7.04–7.02 (m, 2H), 6.80–6.78 (m, 2H), 3.76 (s, 3H), 2.44 
(t, 2H, J = 7.6 Hz), 2.21–2.17 (m, 2H), 1.62–1.57 (m, 2H), 1.48–1.44 (m, 2H), 1.20–1.11 (m, 5H), 
0.75–0.71 (m, 3H). 
13C NMR (CDCl3) δ 173.6, 157.6, 143.0, 134.8, 129.2, 129.2–125.2 (broad), 113.7, 55.3, 38.4, 35.3, 
32.8, 32.4, 29.0, 28.6, 25.5, 10.7. 
FT-IR (film) 2931, 2858, 1674, 1594, 1512, 1491, 1457, 1374, 1246, 1035, 756, 702 cm–1. 
MS (EI) m/z (M+H+) calcd for C28H34NO2: 416, found: 416. 
[α]24D = 1.3 (c = 1.30, CHCl3; obtained with (R,R)-1). 
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4-Ethyl-N-methoxy-N-methyl-7-phenylheptanamide (eq 8).  The title compound was 
prepared according to the general procedure, except that potassium iodide (21 mg, 0.13 mmol; 
water content: 180 ppm) was added to the vial containing NiBr2 • diglyme and 1, before the 
solvent was added.  4-Chloro-N-methoxy-N-methylhexanamide (97 mg, 0.50 mmol) was used, 
along with a solution of the alkylborane prepared by hydroboration of allylbenzene with 9-BBN 
dimer (1.5 M in Et2O; 670 µL, 1.0 mmol).  Colorless oil. 
First run: 87 mg (63%, 86% ee).  Second run: 86 mg (62%, 86% ee). 
The ee was determined by HPLC analysis (CHIRALPAK OJ-H, 1% i-PrOH in hexanes; 1.0 
mL/min; retention times (when (R,R)-1 is employed): 14.2 min (minor), 15.0 min (major)). 
  S–15 
1H NMR (CDCl3) δ 7.24–7.22 (m, 2H), 7.16–7.12 (m, 3H), 3.62 (s, 3H), 3.14 (s, 3H), 2.56 (t, 2H, J 
= 7.6 Hz), 2.33 (t, 2H, J = 7.6 Hz), 1.62–1.54 (m, 4H), 1.33–1.24 (m, 5H), 0.86 (t, 3H, J = 7.2 Hz). 
13C NMR (CDCl3) δ 175.0, 142.8, 128.4, 128.2, 125.6, 61.2, 38.5, 36.3, 32.5, 32.2, 29.4, 28.5, 27.9, 
25.6, 10.8. 
FT-IR (film) 2930, 1670, 1457, 1382, 1003, 747, 699 cm–1. 
MS (EI) m/z (M+H+) calcd for C17H28NO2: 278, found: 278. 
[α]24D = 0.42 (c = 4.40, CHCl3; obtained with (R,R)-1). 
 
 
N
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N,N,4-Triphenylhexanamide (eq 10 and eq 9).  The title compound was prepared according 
to the general procedure, using 4-chloro-N,N-diphenylhexanamide (151 mg, 0.50 mmol), along 
with a solution of 4,4,5,5-tetramethyl-2-phenyl-1,3,2-dioxaborolane (Aldrich; diluted to 1.5 M in 
Et2O; 670 µL, 1.0 mmol).  Colorless oil. 
First run: 81 mg (47%, 83% ee).  Second run: 81 mg (47%, 81% ee). 
The ee was determined by HPLC analysis (CHIRALPAK OD-H, 3% i-PrOH in hexanes; 1.0 
mL/min; retention times (when ligand (R,R)-1 is employed): 16.0 min (minor), 17.5 min 
(major)). 
1H NMR (CDCl3) δ 7.28–7.00 (m, 15H), 2.41–2.40 (m, 1H), 2.09–2.03 (m, 3H), 1.85–1.75 (m, 
1H), 1.62–1.48 (m, 2H), 0.72 (t, 3H, J = 7.2 Hz). 
13C NMR (CDCl3) δ 173.2, 144.7, 142.8, 128.2, 127.8, 126.0, 130.0–125.0 (broad), 47.0, 33.3, 31.8, 
29.8, 12.1.  
FT-IR (film) 3060, 2827, 1680, 1593, 1492, 1375, 1270, 756, 700 cm–1. 
MS (ESI/APCI) m/z (M+H+) calcd for C24H26NO: 344, found: 344. 
[α]25D = 11 (c = 1.80, CHCl3; obtained with (R,R)-1). 
When B-phenyl-(9-BBN)11 was employed instead of 4,4,5,5-tetramethyl-2-phenyl-1,3,2-
dioxaborolane (eq 9): First run: 75 mg (44%, 80% ee).  Second run: 77 mg (45%, 78% ee). 
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4-Cyclopropyl-N,N-diphenylhexanamide (eq 11).  The title compound was prepared 
according to the general procedure, except that Et2O was the only solvent (0.08 M) and the 
catalyst loading was doubled: NiBr2 • diglyme (35.2 mg, 0.10 mmol) and 1 (29 mg, 0.12 mmol).  4-
Chloro-6-methyl-N,N-diphenylheptanamide (165 mg, 0.50 mmol) was used, along with a 
solution of B-cyclopropyl-(9-BBN) (1.5 M in Et2O; 670 µL, 1.0 mmol).  Colorless oil. 
                                                
(11) Fang, G. Y.; Wallner, O. A.; Di Blasio, N.; Ginesta, X.; Harvey, J. N.; Aggarwal, V. K. J. Am. 
Chem. Soc. 2007, 129, 14632–14639. 
  S–16 
First run: 108 mg (68%, 84% ee).  Second run: 109 mg (71%, 83% ee). 
The ee was determined by HPLC analysis (CHIRALPAK OJ-H, 1% i-PrOH in hexanes; 1.0 
mL/min; retention times (when (R,R)-1 is employed): 14.2 min (minor), 15.0 min (major)). 
1H NMR (CDCl3) δ 7.33–7.00 (m, 10H), 2.42–2.27 (m, 2H), 1.82–1.67 (m, 2H), 1.32–1.25 (m, 
2H), 0.84 (t, 3H, J = 7.2 Hz), 0.44–0.39 (m, 1H), 0.32–0.29 (m, 3H), –0.03– –0.10 (m, 2H). 
13C NMR (CDCl3) δ 173.8, 143.1, 129.3–126.5 (broad), 44.4, 33.2, 30.3, 27.5, 15.5, 11.3, 4.0, 3.6. 
FT-IR (film) 2961, 2924, 1675, 1491, 1373, 1271, 756, 702, 693 cm–1. 
MS (EI) m/z (M+H+) calcd for C21H26NO: 308, found: 308. 
[α]24D = –0.80 (c = 1.54, CHCl3; obtained with (S,S)-1). 
 
 
V.  Transformation of the Cross-Coupling Products 
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(S)-4-Ethyl-7-(4-methoxyphenyl)heptan-1-ol (eq 3).  (S)-7-(4-Methoxyphenyl)-4-ethyl-N,N-
diphenylheptanamide (100 mg, 0.24 mmol; 89% ee) and THF (13 mL) were added to an oven-
dried two-neck round-bottom flask under nitrogen.  This solution was cooled to 0 °C, and a 
solution of lithium aluminum hydride (1.45 mL, 2.9 mmol; 2.0 M in THF) was added dropwise 
with stirring.  The mixture was allowed to warm to room temperature, and it was stirred for 12 
h.  The reaction mixture was then cooled to 0 °C, and the reaction was quenched by the addition 
of water (1 mL).  The mixture was filtered through Celite, which was washed with THF.  The 
filtrate was concentrated, and the residue was purified by flash chromatography with 10→70% 
Et2O/hexanes, which furnished the product as a clear oil.  First run: 55 mg (92%, 88% ee).  
Second run: 57 mg (95%, 88% ee). 
The ee was determined by HPLC analysis (CHIRALPAK IC, 2% i-PrOH in hexanes; 1.0 
mL/min; retention times: 41.9 min (minor), 44.0 min (major)). 
1H NMR (CDCl3) δ 7.07 (d, 2H, J = 8.0 Hz), 6.81–6.79 (m, 2H), 3.76 (s, 3H), 3.58 (t, 2H, J = 6.7 
Hz), 2.50 (t, 2H, J = 8.0 Hz), 1.54 (s, 1H), 1.54–1.50 (m, 4H), 1.28–1.26 (m, 7H), 0.81 (t, 3H, J = 6.8 
Hz). 
13C NMR (CDCl3) δ 157.6, 134.9, 129.2, 113.7, 63.5, 55.3, 38.6, 35.5, 32.7, 30.0, 29.1, 28.9, 25.8, 
10.8. 
FT-IR (film) 3336 (broad), 2932, 2858, 2360, 2340, 1512, 1457, 1419, 1245, 1039, 829. 
MS (EI) m/z (M+H+) calcd for C16H27O2: 251, found: 251. 
[α]24D = –2.0  (c = 2.67, CHCl3). 
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92%
(4)
NaOH
EtOH/water, 90 °C
R = (CH2)3(p-anisyl)
N
Et
O
RPh
Ph
HO
Et
O
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(S)-4-Ethyl-7-(4-methoxyphenyl)heptanoic acid (eq 4).  (S)-7-(4-Methoxyphenyl)-4-ethyl-
N,N-diphenylheptanamide (100 mg, 0.24 mmol; 89% ee), EtOH (7 mL), water (0.5 mL), and then 
sodium hydroxide (0.93 mg of a 30% w/w solution) were added to a 20-mL vial, which was 
then sealed with a septum cap and heated to 90 °C for 8 h.  The reaction mixture was allowed to 
cool to room temperature, and then 2 N HCl (2 mL) was added.  The mixture was transferred to 
a separatory funnel, to which Et2O (50 mL) and brine (50 mL) were added.  The layers were 
separated, and the aqueous layer was washed with Et2O (50 mL x2).  The combined organic 
layers were dried over magnesium sulfate, filtered, and concentrated.  The product was purified 
by flash chromatography with 10→70% Et2O/hexanes, which furnished the product as a clear 
oil.  First run: 57 mg (90%, 88% ee).  Second run: 59 mg (93%, 88% ee). 
The ee was determined by HPLC analysis (CHIRALPAK IC, 1% i-PrOH in hexanes; 1.0 
mL/min; retention times: 24.7 min (major), 27.9 min (minor)). 
1H NMR (CDCl3) δ 7.04 (d, 2H, J = 8.4 Hz), 6.86 (d, 2H, J = 8.4 Hz), 3.77 (s, 3H), 2.51 (t, 2H, J = 
7.6 Hz), 2.29 (t, 2H, J = 7.6 Hz), 1.61–1.51 (m, 4H), 1.29–1.26 (m, 5H), 0.81 (t, 3H, J = 6.8 Hz). 
13C NMR (CDCl3) δ 180.1, 157.8, 134.9, 129.4, 113.9, 55.4, 38.4, 35.5, 32.5, 31.7, 28.8, 28.1, 25.6, 
10.9. 
FT-IR (film) 2932 (broad), 2859, 1708, 1512, 1457, 1300, 1245, 1177, 1039, 829. 
MS (EI) m/z (M+H+) calcd for C16H25O3: 265, found: 265. 
[α]24D = –0.62  (c = 2.22, CHCl3). 
 
 
O
NH
1.1 equiv
5% Zr(NMe2)4
toluene, 50 °CN
Et
O
R
(5)
Ph
Ph
R = (CH2)3(p-anisyl) 86%
N
Et
O
RO
 
(S)-4-Ethyl-7-(4-methoxyphenyl)-1-morpholinoheptan-1-one (eq 5) (modified from a 
literature method12).  In a nitrogen-filled glovebox, activated molecular sieves (20 mg; 4 Å), (S)-
4-ethyl-7-(4-methoxyphenyl)-N,N-diphenylheptanamide (50 mg, 0.12 mmol; 89% ee), and 
toluene (0.36 mL; anhydrous, Aldrich) were added to a flame-dried 4-mL vial equipped with a 
stir bar.  The mixture was stirred for 20 minutes, and then it was filtered through a 2 µm 
acrodisc filter into another flame-dried 4-mL vial equipped with a stir bar (the original vial was 
rinsed with toluene (0.1 mL x2), and the washings were filtered through the acrodisc into the 
second vial).  Freshly distilled morpholine (23 µL, 0.27 mmol) was added to the vial by syringe.  
In another flame-dried 4-mL vial, a stock solution of Zr(NMe2)4 in anhydrous toluene was 
                                                
(12) Stephenson, N. A.; Zhu, J.; Gellman, S. H.; Stahl, S. S. J. Am. Chem. Soc. 2009, 131, 
10003−10008. 
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prepared (10.8 mg per 1.0 mL of toluene).  This solution (143 µL, 1.6 mg, 0.0060 mmol) was 
added to the solution of amine and amide, immediately resulting in a light-yellow solution.  The 
vial was sealed with a teflon-lined septum cap, and the mixture was stirred at 50 °C for 10 
hours.  The reaction mixture was then allowed to cool to room temperature, the solvent was 
removed, and the product was purified by reverse-phase flash chromatography on C-18 silica 
gel with 10→100% acetonitrile/water. 
A second run was conducted using (R)-4-ethyl-7-(4-methoxyphenyl)-N,N-
diphenylheptanamide and afforded (R)-4-ethyl-7-(4-methoxyphenyl)-1-morpholinoheptan-1-
one. 
First run: 35 mg (87%, 89% ee).  Second run: 34 mg (85%, 89% ee). 
The ee was determined by HPLC analysis (CHIRALPAK AD-H, 3% i-PrOH in hexanes; 1.0 
mL/min; retention times (when (S)-4-ethyl-7-(4-methoxyphenyl)-N,N-diphenylheptanamide is 
employed): 28.6 min (major), 30.7 min (minor)). 
1H NMR (CDCl3) δ 7.05 (d, 2H, J = 5.2 Hz), 6.79 (d, 2H, J = 4.8 Hz), 3.75 (s, 3H), 3.64–3.57 (m, 
5H), 3.38 (t, 2H, J = 5.2 Hz), 2.92 (d, 1H, J = 16.8 Hz), 2.50 (t, 2H, J = 7.6 Hz), 2.20 (t, 2H), 1.58–1.50 
(m, 4H), 1.29–1.28 (m, 5H), 0.81 (t, 3H, J = 7.1 Hz). 
13C NMR (CDCl3) δ 172.1, 157.7, 134.7, 129.3, 113.7, 67.0, 66.7, 55.3, 46.0, 41.9, 38.6, 35.3, 32.3, 
30.5, 28.6, 28.5, 25.7, 10.8. 
FT-IR (film) 2930, 2856, 2361, 2339, 1653, 1512, 1457, 1300, 1245, 1116, 1035, 830 cm–1. 
MS (EI) m/z (M+H+) calcd for C20H32NO3: 334, found: 334. 
[α]24D = 0.97 (c = 0.95, CHCl3; (S)-4-ethyl-7-(4-methoxyphenyl)-1-morpholinoheptan-1-one). 
 
 
VI.  Determination of Absolute Configuration 
 
Assignment of absolute configuration of the γ-alkylated products.  The absolute 
configuration of the product of entry 2 of Table 1 (using ligand (S,S)-1) was determined by X-ray 
crystallography.  The absolute configurations of the other γ-alkylation products were assigned 
by analogy. 
N
Me
O
Ph
Ph
 
The cross-coupling product was purified to >99% ee by chiral HPLC (CHIRALPAK AD-H).  
Crystals suitable for X-ray structural analysis were obtained by solvent evaporation of a pentane 
solution. 
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Half of the molecule (C2 - C12) was modeled as a two-part disorder (68:32).  Pictured above 
is one of the two modeled structures. 
Absolute configuration: The Flack test is inconclusive due to quality of the data.  However, 
the method by Spek and Hooft, which is based on Bayesian statistics, results in the following 
probabilities: The probability P2 of the model to be correct assuming that the sample is 
KNOWN to be enantiomerically pure is 1.0.  The probability P3 of the model to be correct 
assuming that the structure is either right or wrong or a 50:50 racemic twin is 0.90.  The 
probability of the model to be a 50:50 racemic twin is 0.10.  The inverted model gives rise to 
opposite results in the Bayesian statistics, further improving the confidence in the absolute 
configuration as determined by X-ray diffraction. 
 
Table 1.  Crystal data and structure refinement for x10032_t4. 
Identification code  x10032_t4 
Empirical formula  C24 H31 N O 
Formula weight  349.50 
Temperature  100(2) K 
Wavelength  1.54178 ≈ 
Crystal system  Monoclinic 
Space group  C2 
Unit cell dimensions a = 17.5701(5) ≈ α= 90∞. 
 b = 5.6668(2) ≈ β= 96.082(2)∞. 
 c = 20.4694(7) ≈ γ = 90∞. 
Volume 2026.59(12) ≈3 
Z 4 
Density (calculated) 1.145 Mg/m3 
Absorption coefficient 0.524 mm-1 
F(000) 760 
Crystal size 0.20 x 0.02 x 0.02 mm3 
Theta range for data collection 2.17 to 67.77∞. 
Index ranges -20<=h<=20, -6<=k<=5, -24<=l<=24 
Reflections collected 3273 
Independent reflections 3273 [R(int) = 0.0000] 
Completeness to theta = 67.77∞ 99.6 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9922 and 0.9024 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3273 / 383 / 326 
Goodness-of-fit on F2 1.054 
Final R indices [I>2sigma(I)] R1 = 0.0476, wR2 = 0.1306 
R indices (all data) R1 = 0.0506, wR2 = 0.1328 
Absolute structure parameter -0.1(4) 
Largest diff. peak and hole 0.329 and -0.159 e.≈-3 
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Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (≈2x 103) 
for x10032_t4.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
O(1) 7176(1) 2053(3) 3198(1) 48(1) 
C(1) 6488(1) 2303(4) 3075(1) 43(1) 
C(2) 6151(1) 3704(5) 2478(1) 51(1) 
C(3) 6590(2) 3275(8) 1842(2) 43(1) 
C(4) 6577(3) 764(9) 1616(2) 43(1) 
C(5) 5760(2) -186(9) 1445(2) 61(1) 
C(6) 7008(2) 374(9) 1005(2) 60(1) 
C(7) 7831(3) 1169(12) 1064(2) 56(1) 
C(8) 8309(3) -92(13) 1632(2) 75(2) 
C(9) 9135(3) 511(18) 1645(2) 111(2) 
C(10) 9450(3) -196(18) 999(3) 111(2) 
C(11) 8997(3) 1136(19) 439(3) 104(2) 
C(12) 8173(3) 544(15) 409(2) 90(2) 
C(3A) 6735(5) 4233(17) 2105(5) 51(2) 
C(4A) 7045(4) 2140(17) 1744(4) 54(2) 
C(5A) 6405(7) 710(20) 1351(7) 70(3) 
C(6A) 7653(5) 3111(17) 1357(4) 60(2) 
C(7A) 8044(7) 1400(20) 943(6) 62(2) 
C(8A) 8406(6) -686(18) 1358(4) 59(2) 
C(9A) 8843(5) -2260(20) 967(5) 74(2) 
C(10A) 9431(6) -1030(20) 583(5) 80(3) 
C(11A) 9095(8) 1110(30) 193(6) 85(3) 
C(12A) 8672(6) 2730(20) 614(5) 75(2) 
N(1) 5976(1) 1306(3) 3457(1) 40(1) 
C(21) 6230(1) -247(4) 3992(1) 39(1) 
C(22) 5988(1) 123(5) 4602(1) 54(1) 
C(23) 6207(2) -1440(6) 5108(1) 64(1) 
C(24) 6666(1) -3361(5) 5012(1) 54(1) 
C(25) 6911(1) -3700(5) 4395(1) 48(1) 
C(26) 6690(1) -2173(4) 3891(1) 42(1) 
C(31) 5162(1) 1771(4) 3363(1) 39(1) 
C(32) 4873(1) 3876(5) 3574(1) 55(1) 
C(33) 4088(2) 4251(6) 3485(2) 66(1) 
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C(34) 3604(1) 2565(6) 3209(1) 62(1) 
C(35) 3889(1) 464(6) 3008(1) 54(1) 
C(36) 4676(1) 64(4) 3084(1) 41(1) 
________________________________________________________________________________ 
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 Table 3.   Bond lengths [≈] and angles [∞] for  x10032_t4. 
_____________________________________________________  
O(1)-C(1)  1.216(3) 
C(1)-N(1)  1.374(3) 
C(1)-C(2)  1.524(4) 
C(2)-C(3A)  1.374(8) 
C(2)-C(3)  1.600(4) 
C(2)-H(2A)  0.9900 
C(2)-H(2B)  0.9900 
C(2)-H(2C)  0.9900 
C(2)-H(2D)  0.9900 
C(3)-C(4)  1.496(7) 
C(3)-H(3A)  0.9900 
C(3)-H(3B)  0.9900 
C(4)-C(5)  1.539(6) 
C(4)-C(6)  1.544(5) 
C(4)-H(4)  1.0000 
C(5)-H(5A)  0.9800 
C(5)-H(5B)  0.9800 
C(5)-H(5C)  0.9800 
C(6)-C(7)  1.508(7) 
C(6)-H(6A)  0.9900 
C(6)-H(6B)  0.9900 
C(7)-C(8)  1.537(7) 
C(7)-C(12)  1.566(5) 
C(7)-H(7)  1.0000 
C(8)-C(9)  1.489(7) 
C(8)-H(8A)  0.9900 
C(8)-H(8B)  0.9900 
C(9)-C(10)  1.540(8) 
C(9)-H(9A)  0.9900 
C(9)-H(9B)  0.9900 
C(10)-C(11)  1.525(9) 
C(10)-H(10A)  0.9900 
C(10)-H(10B)  0.9900 
C(11)-C(12)  1.480(8) 
C(11)-H(11A)  0.9900 
C(11)-H(11B)  0.9900 
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C(12)-H(12A)  0.9900 
C(12)-H(12B)  0.9900 
C(3A)-C(4A)  1.529(12) 
C(3A)-H(3A1)  0.9900 
C(3A)-H(3A2)  0.9900 
C(4A)-C(6A)  1.500(10) 
C(4A)-C(5A)  1.543(13) 
C(4A)-H(4A)  1.0000 
C(5A)-H(5A1)  0.9800 
C(5A)-H(5A2)  0.9800 
C(5A)-H(5A3)  0.9800 
C(6A)-C(7A)  1.500(13) 
C(6A)-H(6A1)  0.9900 
C(6A)-H(6A2)  0.9900 
C(7A)-C(12A)  1.547(11) 
C(7A)-C(8A)  1.554(11) 
C(7A)-H(7A)  1.0000 
C(8A)-C(9A)  1.468(11) 
C(8A)-H(8A1)  0.9900 
C(8A)-H(8A2)  0.9900 
C(9A)-C(10A)  1.530(11) 
C(9A)-H(9A1)  0.9900 
C(9A)-H(9A2)  0.9900 
C(10A)-C(11A)  1.533(12) 
C(10A)-H(10C)  0.9900 
C(10A)-H(10D)  0.9900 
C(11A)-C(12A)  1.508(13) 
C(11A)-H(11C)  0.9900 
C(11A)-H(11D)  0.9900 
C(12A)-H(12C)  0.9900 
C(12A)-H(12D)  0.9900 
N(1)-C(21)  1.438(3) 
N(1)-C(31)  1.446(2) 
C(21)-C(22)  1.377(3) 
C(21)-C(26)  1.387(3) 
C(22)-C(23)  1.385(4) 
C(22)-H(22)  0.9500 
C(23)-C(24)  1.382(4) 
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C(23)-H(23)  0.9500 
C(24)-C(25)  1.389(4) 
C(24)-H(24)  0.9500 
C(25)-C(26)  1.371(3) 
C(25)-H(25)  0.9500 
C(26)-H(26)  0.9500 
C(31)-C(36)  1.374(3) 
C(31)-C(32)  1.384(3) 
C(32)-C(33)  1.388(4) 
C(32)-H(32)  0.9500 
C(33)-C(34)  1.361(5) 
C(33)-H(33)  0.9500 
C(34)-C(35)  1.370(4) 
C(34)-H(34)  0.9500 
C(35)-C(36)  1.394(3) 
C(35)-H(35)  0.9500 
C(36)-H(36)  0.9500 
 
O(1)-C(1)-N(1) 122.1(2) 
O(1)-C(1)-C(2) 121.3(2) 
N(1)-C(1)-C(2) 116.62(18) 
C(3A)-C(2)-C(1) 108.0(4) 
C(3A)-C(2)-C(3) 29.5(4) 
C(1)-C(2)-C(3) 113.2(2) 
C(3A)-C(2)-H(2A) 84.5 
C(1)-C(2)-H(2A) 108.9 
C(3)-C(2)-H(2A) 108.9 
C(3A)-C(2)-H(2B) 134.2 
C(1)-C(2)-H(2B) 108.9 
C(3)-C(2)-H(2B) 108.9 
H(2A)-C(2)-H(2B) 107.8 
C(3A)-C(2)-H(2C) 110.1 
C(1)-C(2)-H(2C) 110.1 
C(3)-C(2)-H(2C) 81.5 
H(2A)-C(2)-H(2C) 130.8 
H(2B)-C(2)-H(2C) 30.3 
C(3A)-C(2)-H(2D) 110.1 
C(1)-C(2)-H(2D) 110.1 
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C(3)-C(2)-H(2D) 128.5 
H(2A)-C(2)-H(2D) 28.2 
H(2B)-C(2)-H(2D) 81.2 
H(2C)-C(2)-H(2D) 108.4 
C(4)-C(3)-C(2) 113.8(3) 
C(4)-C(3)-H(3A) 108.8 
C(2)-C(3)-H(3A) 108.8 
C(4)-C(3)-H(3B) 108.8 
C(2)-C(3)-H(3B) 108.8 
H(3A)-C(3)-H(3B) 107.7 
C(3)-C(4)-C(5) 112.7(4) 
C(3)-C(4)-C(6) 113.2(4) 
C(5)-C(4)-C(6) 106.9(3) 
C(3)-C(4)-H(4) 107.9 
C(5)-C(4)-H(4) 107.9 
C(6)-C(4)-H(4) 107.9 
C(4)-C(5)-H(5A) 109.5 
C(4)-C(5)-H(5B) 109.5 
H(5A)-C(5)-H(5B) 109.5 
C(4)-C(5)-H(5C) 109.5 
H(5A)-C(5)-H(5C) 109.5 
H(5B)-C(5)-H(5C) 109.5 
C(7)-C(6)-C(4) 116.2(3) 
C(7)-C(6)-H(6A) 108.2 
C(4)-C(6)-H(6A) 108.2 
C(7)-C(6)-H(6B) 108.2 
C(4)-C(6)-H(6B) 108.2 
H(6A)-C(6)-H(6B) 107.4 
C(6)-C(7)-C(8) 111.3(4) 
C(6)-C(7)-C(12) 108.4(4) 
C(8)-C(7)-C(12) 108.4(4) 
C(6)-C(7)-H(7) 109.6 
C(8)-C(7)-H(7) 109.6 
C(12)-C(7)-H(7) 109.6 
C(9)-C(8)-C(7) 111.1(5) 
C(9)-C(8)-H(8A) 109.4 
C(7)-C(8)-H(8A) 109.4 
C(9)-C(8)-H(8B) 109.4 
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C(7)-C(8)-H(8B) 109.4 
H(8A)-C(8)-H(8B) 108.0 
C(8)-C(9)-C(10) 111.4(5) 
C(8)-C(9)-H(9A) 109.4 
C(10)-C(9)-H(9A) 109.4 
C(8)-C(9)-H(9B) 109.4 
C(10)-C(9)-H(9B) 109.4 
H(9A)-C(9)-H(9B) 108.0 
C(11)-C(10)-C(9) 108.1(5) 
C(11)-C(10)-H(10A) 110.1 
C(9)-C(10)-H(10A) 110.1 
C(11)-C(10)-H(10B) 110.1 
C(9)-C(10)-H(10B) 110.1 
H(10A)-C(10)-H(10B) 108.4 
C(12)-C(11)-C(10) 110.5(6) 
C(12)-C(11)-H(11A) 109.6 
C(10)-C(11)-H(11A) 109.6 
C(12)-C(11)-H(11B) 109.6 
C(10)-C(11)-H(11B) 109.6 
H(11A)-C(11)-H(11B) 108.1 
C(11)-C(12)-C(7) 112.0(5) 
C(11)-C(12)-H(12A) 109.2 
C(7)-C(12)-H(12A) 109.2 
C(11)-C(12)-H(12B) 109.2 
C(7)-C(12)-H(12B) 109.2 
H(12A)-C(12)-H(12B) 107.9 
C(2)-C(3A)-C(4A) 115.1(7) 
C(2)-C(3A)-H(3A1) 108.5 
C(4A)-C(3A)-H(3A1) 108.5 
C(2)-C(3A)-H(3A2) 108.5 
C(4A)-C(3A)-H(3A2) 108.5 
H(3A1)-C(3A)-H(3A2) 107.5 
C(6A)-C(4A)-C(3A) 106.4(7) 
C(6A)-C(4A)-C(5A) 116.0(8) 
C(3A)-C(4A)-C(5A) 112.5(8) 
C(6A)-C(4A)-H(4A) 107.2 
C(3A)-C(4A)-H(4A) 107.2 
C(5A)-C(4A)-H(4A) 107.2 
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C(4A)-C(5A)-H(5A1) 109.5 
C(4A)-C(5A)-H(5A2) 109.5 
H(5A1)-C(5A)-H(5A2) 109.5 
C(4A)-C(5A)-H(5A3) 109.5 
H(5A1)-C(5A)-H(5A3) 109.5 
H(5A2)-C(5A)-H(5A3) 109.5 
C(7A)-C(6A)-C(4A) 117.2(8) 
C(7A)-C(6A)-H(6A1) 108.0 
C(4A)-C(6A)-H(6A1) 108.0 
C(7A)-C(6A)-H(6A2) 108.0 
C(4A)-C(6A)-H(6A2) 108.0 
H(6A1)-C(6A)-H(6A2) 107.3 
C(6A)-C(7A)-C(12A) 108.9(9) 
C(6A)-C(7A)-C(8A) 111.5(9) 
C(12A)-C(7A)-C(8A) 109.8(9) 
C(6A)-C(7A)-H(7A) 108.9 
C(12A)-C(7A)-H(7A) 108.9 
C(8A)-C(7A)-H(7A) 108.9 
C(9A)-C(8A)-C(7A) 111.8(8) 
C(9A)-C(8A)-H(8A1) 109.2 
C(7A)-C(8A)-H(8A1) 109.2 
C(9A)-C(8A)-H(8A2) 109.2 
C(7A)-C(8A)-H(8A2) 109.2 
H(8A1)-C(8A)-H(8A2) 107.9 
C(8A)-C(9A)-C(10A) 115.1(9) 
C(8A)-C(9A)-H(9A1) 108.5 
C(10A)-C(9A)-H(9A1) 108.5 
C(8A)-C(9A)-H(9A2) 108.5 
C(10A)-C(9A)-H(9A2) 108.5 
H(9A1)-C(9A)-H(9A2) 107.5 
C(9A)-C(10A)-C(11A) 112.6(9) 
C(9A)-C(10A)-H(10C) 109.1 
C(11A)-C(10A)-H(10C) 109.1 
C(9A)-C(10A)-H(10D) 109.1 
C(11A)-C(10A)-H(10D) 109.1 
H(10C)-C(10A)-H(10D) 107.8 
C(12A)-C(11A)-C(10A) 111.7(9) 
C(12A)-C(11A)-H(11C) 109.3 
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C(10A)-C(11A)-H(11C) 109.3 
C(12A)-C(11A)-H(11D) 109.3 
C(10A)-C(11A)-H(11D) 109.3 
H(11C)-C(11A)-H(11D) 107.9 
C(11A)-C(12A)-C(7A) 111.7(10) 
C(11A)-C(12A)-H(12C) 109.3 
C(7A)-C(12A)-H(12C) 109.3 
C(11A)-C(12A)-H(12D) 109.3 
C(7A)-C(12A)-H(12D) 109.3 
H(12C)-C(12A)-H(12D) 107.9 
C(1)-N(1)-C(21) 121.02(17) 
C(1)-N(1)-C(31) 123.14(19) 
C(21)-N(1)-C(31) 115.82(16) 
C(22)-C(21)-C(26) 119.7(2) 
C(22)-C(21)-N(1) 119.7(2) 
C(26)-C(21)-N(1) 120.47(19) 
C(21)-C(22)-C(23) 119.5(2) 
C(21)-C(22)-H(22) 120.3 
C(23)-C(22)-H(22) 120.3 
C(24)-C(23)-C(22) 121.2(2) 
C(24)-C(23)-H(23) 119.4 
C(22)-C(23)-H(23) 119.4 
C(23)-C(24)-C(25) 118.7(3) 
C(23)-C(24)-H(24) 120.7 
C(25)-C(24)-H(24) 120.7 
C(26)-C(25)-C(24) 120.4(2) 
C(26)-C(25)-H(25) 119.8 
C(24)-C(25)-H(25) 119.8 
C(25)-C(26)-C(21) 120.5(2) 
C(25)-C(26)-H(26) 119.7 
C(21)-C(26)-H(26) 119.7 
C(36)-C(31)-C(32) 120.2(2) 
C(36)-C(31)-N(1) 119.3(2) 
C(32)-C(31)-N(1) 120.4(2) 
C(31)-C(32)-C(33) 118.9(3) 
C(31)-C(32)-H(32) 120.5 
C(33)-C(32)-H(32) 120.5 
C(34)-C(33)-C(32) 121.0(3) 
  S–29 
C(34)-C(33)-H(33) 119.5 
C(32)-C(33)-H(33) 119.5 
C(33)-C(34)-C(35) 120.2(2) 
C(33)-C(34)-H(34) 119.9 
C(35)-C(34)-H(34) 119.9 
C(34)-C(35)-C(36) 119.8(3) 
C(34)-C(35)-H(35) 120.1 
C(36)-C(35)-H(35) 120.1 
C(31)-C(36)-C(35) 119.9(2) 
C(31)-C(36)-H(36) 120.1 
C(35)-C(36)-H(36) 120.1 
_____________________________________________________________ 
Symmetry transformations used to generate equivalent atoms: 
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Table 4.  Anisotropic displacement parameters  (≈2x 103) for x10032_t4.  The anisotropic 
displacement factor exponent takes the form:  -2π2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
O(1) 29(1)  52(1) 64(1)  -8(1) 13(1)  -7(1) 
C(1) 34(1)  36(1) 61(1)  -10(1) 16(1)  -4(1) 
C(2) 38(1)  43(1) 75(2)  1(1) 18(1)  4(1) 
C(3) 40(2)  44(2) 47(2)  13(2) 12(2)  -1(2) 
C(4) 40(2)  53(2) 34(2)  6(2) 3(2)  0(2) 
C(5) 59(2)  62(3) 62(2)  2(2) 4(2)  -10(2) 
C(6) 61(2)  83(3) 35(2)  -2(2) 8(1)  7(2) 
C(7) 58(2)  86(3) 27(2)  3(2) 14(2)  8(2) 
C(8) 64(2)  110(4) 52(2)  8(3) 7(2)  23(3) 
C(9) 55(2)  204(7) 75(3)  19(4) 8(2)  18(4) 
C(10) 57(2)  170(7) 112(4)  11(4) 37(3)  26(4) 
C(11) 72(3)  181(6) 68(3)  -1(4) 43(3)  18(3) 
C(12) 69(2)  158(5) 48(2)  -20(3) 22(2)  9(3) 
C(3A) 48(4)  39(5) 68(5)  15(3) 11(3)  -2(3) 
C(4A) 47(4)  57(5) 59(4)  4(3) 10(3)  18(3) 
C(5A) 63(6)  63(6) 85(9)  -11(6) 12(6)  16(4) 
C(6A) 74(4)  59(5) 47(4)  13(3) 8(3)  11(3) 
C(7A) 62(5)  82(5) 44(5)  12(4) 12(3)  15(4) 
C(8A) 78(5)  63(5) 36(4)  5(3) 11(4)  6(4) 
C(9A) 61(5)  76(6) 88(6)  19(5) 21(4)  17(4) 
C(10A) 72(5)  107(7) 64(5)  17(5) 22(4)  12(5) 
C(11A) 74(6)  123(7) 61(6)  26(5) 24(4)  12(5) 
C(12A) 85(5)  87(6) 55(4)  25(4) 16(4)  2(4) 
N(1) 28(1)  38(1) 57(1)  -5(1) 11(1)  0(1) 
C(21) 24(1)  39(1) 54(1)  -10(1) 4(1)  -4(1) 
C(22) 53(1)  54(2) 53(1)  -15(1) -1(1)  17(1) 
C(23) 69(2)  77(2) 44(1)  -13(1) -5(1)  23(2) 
C(24) 46(1)  58(2) 56(1)  -5(1) -10(1)  8(1) 
C(25) 29(1)  45(2) 71(2)  -7(1) 4(1)  0(1) 
C(26) 27(1)  40(1) 61(1)  -9(1) 11(1)  -3(1) 
C(31) 31(1)  36(1) 52(1)  6(1) 14(1)  4(1) 
C(32) 45(1)  42(2) 82(2)  0(1) 28(1)  6(1) 
C(33) 55(2)  50(2) 99(2)  22(2) 45(2)  21(1) 
  S–31 
C(34) 33(1)  79(2) 78(2)  41(2) 27(1)  17(1) 
C(35) 32(1)  74(2) 54(1)  23(1) 5(1)  -6(1) 
C(36) 34(1)  43(1) 46(1)  9(1) 7(1)  -1(1) 
______________________________________________________________________________ 
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Table 5.  Hydrogen coordinates ( x 104) and isotropic  displacement parameters (≈2x 10 3) 
for x10032_t4. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(2A) 6170 5406 2588 61 
H(2B) 5607 3260 2374 61 
H(2C) 5753 2760 2217 61 
H(2D) 5912 5173 2620 61 
H(3A) 6353 4277 1480 52 
H(3B) 7129 3782 1941 52 
H(4) 6832 -220 1981 51 
H(5A) 5783 -1829 1298 92 
H(5B) 5494 772 1093 92 
H(5C) 5481 -108 1835 92 
H(6A) 6992 -1331 899 72 
H(6B) 6727 1214 630 72 
H(7) 7857 2913 1136 67 
H(8A) 8124 377 2054 90 
H(8B) 8242 -1820 1582 90 
H(9A) 9428 -317 2016 133 
H(9B) 9203 2229 1715 133 
H(10A) 10000 214 1018 133 
H(10B) 9396 -1918 928 133 
H(11A) 9066 2855 506 125 
H(11B) 9191 714 17 125 
H(12A) 8104 -1164 319 109 
H(12B) 7890 1419 42 109 
H(3A1) 7161 4939 2396 62 
H(3A2) 6550 5442 1777 62 
H(4A) 7304 1062 2085 65 
H(5A1) 6630 -632 1138 105 
H(5A2) 6131 1721 1016 105 
H(5A3) 6046 126 1649 105 
H(6A1) 7420 4370 1067 72 
H(6A2) 8050 3861 1669 72 
H(7A) 7658 767 592 74 
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H(8A1) 8749 -57 1732 71 
H(8A2) 7995 -1598 1538 71 
H(9A1) 8478 -3126 652 89 
H(9A2) 9113 -3435 1265 89 
H(10C) 9627 -2173 276 96 
H(10D) 9868 -505 894 96 
H(11C) 9514 1992 17 101 
H(11D) 8740 553 -183 101 
H(12C) 8434 4024 338 90 
H(12D) 9040 3442 958 90 
H(22) 5674 1440 4675 64 
H(23) 6038 -1186 5528 77 
H(24) 6812 -4429 5360 65 
H(25) 7234 -4997 4322 58 
H(26) 6853 -2438 3469 51 
H(32) 5206 5045 3777 66 
H(33) 3886 5706 3619 79 
H(34) 3069 2847 3154 74 
H(35) 3550 -716 2819 64 
H(36) 4876 -1385 2943 49 
________________________________________________________________________________ 
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Assignment of absolute configuration of the δ-alkylated product.  γ-Alkylated product (R)-
7-(4-methoxyphenyl)-4-methyl-N,N-diphenylheptanamide, synthesized using (R,R)-1, was 
homologated.  The specific rotation of the final product, 8-(4-methoxyphenyl)-5-methyloctanoic 
acid, was determined. 
 
[!]24D = 1.7 (c = 0.98, CHCl3)
84% ee
prepared with (R,R)-1
OMe
N
Me
O
Ph
Ph 1) LAH
2) TsCl
3) CN
4) KOH
OMe
Me
O
HO
 
(R)-8-(4-Methoxyphenyl)-5-methyloctanoic acid. 
1H NMR (CDCl3) δ 7.07 (d, 2H, J = 8.4 Hz), 6.81 (d, 2H, J = 8.5 Hz), 3.77 (s, 3H), 2.53–2.48 (m, 
2H), 2.32–2.29 (m, 2H), 1.62–1.57 (m, 5H), 1.55–1.41 (m, 3H), 1.31–1.22 (m, 2H), 0.86 (d, 3H, J = 
6.5 Hz). 
13C NMR (CDCl3) δ 180.3, 157.6, 134.9, 129.2, 113.7, 55.3, 36.4, 36.3, 35.3, 34.4, 32.5, 29.2, 22.2, 
19.5. 
FT-IR (film) 2931 (broad), 1708, 1612, 1512, 1463, 1300, 1245, 1177, 1038, 829. 
MS (EI) m/z (M+H+) calcd for C16H25O3: 265, found: 265. 
[α]24D = 1.7 (c = 0.98, CHCl3). 
 
This specific rotation was compared to the product that was generated through the δ-
alkylation illustrated in eq 7 (with (R,R)-1), followed by hydrolysis of the amide.  The specific 
rotations had the same sign. 
 
[!]24D = 1.6 (c = 0.95, CHCl3)
84% ee
prepared with (R,R)-1
NaOH
OMe
Me
O
HO
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